Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 6/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8001171 | 1.00 | KMT2A (0.36) | KMT2ARENRORCGSK3BKCNH2 | |
| SCHEMBL8228289 | 1.00 | KMT2A (0.36) | KMT2ARENRORCGSK3BKCNH2 | |
| SCHEMBL13601245 | 0.93 | KMT2A (0.35) | KMT2ARENRORCGSK3BKCNH2 | |
| SCHEMBL8001572 | 0.93 | KMT2A (0.35) | KMT2ARENRORCGSK3BKCNH2 | |
| SCHEMBL8004948 | 0.90 | REN (0.35) | KMT2ARENRORCKCNH2NPY5R | |
| SCHEMBL8004344 | 0.88 | KMT2A (0.35) | KMT2ARENGSK3BKCNH2TSHR | |
| SCHEMBL4508163 | 0.88 | KMT2A (0.35) | KMT2ARENGSK3BKCNH2TSHR | |
| SCHEMBL8001568 | 0.88 | TSHR (0.40) | RENTSHR | |
| SCHEMBL13601239 | 0.86 | REN (0.35) | KMT2ARENRORCTSHR | |
| SCHEMBL8002690 | 0.86 | REN (0.35) | KMT2ARENRORCTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009106599-A2 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |